

# The Efficacy of Bismuth-based Quadruple and Sequential Therapies in *Helicobacter pylori* Eradication

## *Helikobakter pilori Eradikasyonunda Bizmutlu Dörtlü Tedavi ile Bizmutlu Ardışık Tedavinin Etkinliği*

Adil Coşkun<sup>1</sup>, Mustafa Çelik<sup>2</sup>, Altay Kandemir<sup>1</sup>

<sup>1</sup>Aydın Adnan Menderes University Faculty of Medicine, Department of Gastroenterology, Aydın, Turkey

<sup>2</sup>Pamukkale University Faculty of Medicine, Department of Gastroenterology, Denizli, Turkey



### Keywords

*Helicobacter pylori*, quadruple treatment, sequential treatment

### Anahtar Kelimeler

*Helikobakter pilori*, dörtlü tedavi, ardışık tedavi

Received/Geliş Tarihi : 03.07.2019

Accepted/Kabul Tarihi : 21.08.2019

doi:10.4274/meandros.galenos.2019.08831

### Address for Correspondence/Yazışma Adresi:

Adil Coşkun, Assoc. Prof.,  
Aydın Adnan Menderes University Faculty of  
Medicine, Department of Gastroenterology,  
Aydın, Turkey  
Phone : +90 532 505 24 94  
E-mail : adilcoskun@gmail.com  
ORCID ID: orcid.org/0000-0002-1549-5451

©Meandros Medical and Dental Journal, Published by Galenos Publishing House.  
This is article distributed under the terms of the Creative Commons Attribution NonCommercial 4.0 International Licence (CC BY-NC 4.0).

### Abstract

**Objective:** New therapy regimens are needed for *Helicobacter pylori* (*H. pylori*) eradication because of increased resistance to the commonly used antibiotics. This study aimed to compare the efficacy of bismuth quadruple therapy versus sequential therapy for *H. pylori* eradication.

**Materials and Methods:** Patients who presented with dyspepsia complaints and were diagnosed with *H. pylori* infection by histopathologic examination of biopsies obtained by gastroscopy were evaluated retrospectively. Two hundred and five patients who received bismuth-based quadruple therapy and sequential therapy for *H. pylori* eradication were included in the study. Bismuth-based quadruple therapy group were given pantoprazole 2x40 mg, bismuth subcitrate 4x300 mg, amoxicillin 2x1000 mg and metronidazole 3x500 mg for 14 days. In the bismuth-based sequential therapy group, the protocol was as follows; pantoprazole 2x40 mg (14 days), bismuth subcitrate 4x300 mg (14 days), amoxicillin 2x1000 mg (first 7 days), metronidazole 3x500 mg (second 7 days) and levofloxacin 1x500 mg (second 7 days). Eradication was determined by stool *H. pylori* Antigen test six weeks after the treatment.

**Results:** A total of 102 patients in group 1 and 91 patients in group 2 completed the treatment and there was no significant difference between the two groups ( $p=0.310$ ). *H. pylori* eradication rate showed no significant difference between the two groups ( $p=0.093$ ), while group 1 attained a better eradication rate than group 2 on intention-to-treat, which was statistically significant ( $p=0.033$ ).

**Conclusion:** We achieved better eradication rates with bismuth-based quadruple therapy compared to the sequential therapy. We recommend bismuth-based quadruple regimen as the first-line eradication therapy to avoid drug incompatibilities seen during the sequential regime.

### Öz

**Amaç:** *Helikobakter pilori* (*H. pilori*) eradikasyon tedavisinde kullanılan antibiyotiklere karşı direncin artması nedeniyle yeni tedavi rejimlerine ihtiyaç duyulmaktadır. Bu çalışmada, *H. pilori* eradikasyonunda bizmutlu dörtlü tedavi ile bizmutlu ardışık tedavinin etkinliğini karşılaştırmayı amaçladık.

**Gereç ve Yöntemler:** Dispepsi yakınması ile başvuran, yapılan gastroskopi ile alınan biyopsilerde histolojik inceleme sonrasında *H. pilori* saptanan hastalar retrospektif

olarak değerlendirildi. Eradikasyon tedavisi olarak bizmutlu dörtlü tedavi ve bizmutlu ardışık tedavi alan 231 hasta çalışmaya alındı. Bizmutlu dörtlü tedavi alan gruba; 14 gün boyunca pantoprazol 2x40 mg, bizmut subsitrate 4x300 mg, amoksisilin 2x1000 mg, metronidazol 3x500 mg (14 gün) verilmişti. Bizmutlu ardışık tedavi alan gruba; pantoprazol 2x40 mg (14 gün), bizmut subsitrate 4x300 mg (14 gün), amoksisilin 2x1000 mg (ilk 7 gün), metronidazol 3x500 mg (ikinci 7 gün), levofloksasin 1x500 mg (ikinci 7 gün) verilmişti. Eradikasyon, tedaviden altı hafta sonra gaitada *H. pylori* Antijen testi ile ölçüldü.

**Bulgular:** Grup 1'de 102 hasta, grup 2'de 91 hasta tedaviyi tamamlamış ve her iki grup arasında anlamlı bir fark bulunmamıştır ( $p=0,310$ ). Her iki grup arasında protokol başına eradikasyon oranı açısından anlamlı bir fark bulunmamış ( $p=0,093$ ), grup 1 rejimi intention-to-treat'de grup 2'ye göre daha iyi eradikasyon oranına ulaşmış ve istatistiksel olarak anlamlı bulunmuştur ( $p=0,033$ ).

**Sonuç:** Bizmut bazlı dörtlü tedavi ile ardışık tedaviye oranla daha iyi bir eradikasyon oranlarına ulaştık. Ardışık tedavi sırasında görülebilen ilaç uyumsuzluğu nedeniyle birinci basamak eradikasyon tedavisinde bizmut bazlı dörtlü tedavi rejiminin kullanılmasını önermekteyiz.

## Introduction

*Helicobacter pylori* (*H. pylori*) infection is an important health problem in our country and worldwide. *H. pylori* is the main cause of chronic gastritis and peptic ulcer disease as well as a major risk factor for gastric cancer and mucosa-associated lymphoid tissue lymphoma (1,2). *H. pylori* is also associated with extraintestinal diseases such as idiopathic thrombocytopenic purpura, unexplained iron deficiency anemia, Diabetes Mellitus and atherosclerotic cardiovascular disease (3).

Worldwide prevalence of *H. pylori* infection is expected to be 4.4 billion in 2015, although it is decreasing in Western Europe and North America (4).

The efficacy of the recommended first line therapy for *H. pylori* infection, which was the triple therapy including proton pump inhibitors (PPIs), amoxicillin and clarithromycin, decreased in most countries, hence new treatment strategies are needed (5-7). The Maastricht V consensus meeting recommended bismuth-based quadruple therapy regimens in areas with high clarithromycin and metronidazole resistance (8). Moreover, sequential therapy regimes were also proposed as effective first-line treatment methods, in recent years (9). However, the complexity of the sequential therapy regime is a major disadvantage that threatens its feasibility and success rate.

In this study, we aimed to compare the efficacy of bismuth based quadruple therapy versus sequential therapy for the first-line *H. pylori* eradication therapy.

## Materials and Methods

### Study Design and Population

Patients admitted to two centers of gastroenterology department with dyspepsia complaints between October 2015 and October

2016 and who underwent endoscopic biopsy for *H. pylori* infection with the pre-diagnosis of non-ulcer dyspepsia and who were found positive for *H. pylori* infection in biopsy were retrospectively evaluated in the study.

Biopsy specimens from both antrum and corpus were sent for histopathological evaluation. *H. pylori* status was assessed by pathologists using hematoxylin-eosin and Giemsa staining procedures. Two hundred and five patients who received bismuth based quadruple therapy and sequential therapy for *H. pylori* eradication were included in the study. The written informed consent of the patients' was not received due to archival scan and retrospective study. Patient information was obtained from hospital information system and/or patient files. Patients who had stomach malignancy, gastric surgery history, previous *H. pylori* eradication therapy and who were under 18 years of age were excluded from the study. The study was approved by Non-invasive Clinical Research Ethics Committee of Adnan Menderes University Medical Faculty (protocol no: 2016/1009).

### Treatment Procedures

Bismuth based quadruple therapy group (group 1) was given pantoprazole 2x40 mg (14 days), bismuth subcitrate 4x300 mg (14 days), amoxicillin 2x1000 mg (14 days) and metronidazole 3x500 mg (14 days). Bismuth based sequential therapy group (group 2) was given pantoprazole 2x40 mg (14 days), bismuth subcitrate 4x300 mg (14 days), amoxicillin 2x1000 mg (first 7 days), metronidazole 3x500 mg (second 7 days), levofloxacin 1x500 mg (second 7 days). Eradication was assessed in the stool by *H. pylori* Antigen test after six weeks of treatment, in the period without taking PPI. The stool assay used was the commercially available diagnostic *H. pylori* Antigen Rapid test

(Cer Test Biotec S.L. Zaragoza, Spain). Successful eradication was defined as Negative Stool test while eradication failure as Positive Stool test.

### Statistical Analysis

Compliance of age with normal distribution was assessed by Kolmogorov-Smirnov test. Descriptive statistics were shown as mean (25<sup>th</sup>-75<sup>th</sup> percentile) since it did not show normal distribution. Mann-Whitney U test was applied to compare the groups for age variable. The descriptive statistics of categorical variables were expressed as number (percentage). *H. pylori* eradication rates were assessed with per-protocol (PP) and intention-to-treat (ITT) analyzes. Chi-square analysis was used for comparison with respect to the groups.  $P < 0.05$  was considered statistically significant.

### Results

In our retrospective study, 193 (94.1%) of the 205 patients completed the provided treatment. Twelve patients (5.9%) failed to complete the treatment due to gastrointestinal system (GIS) intolerance and non compliance with drugs. GIS intolerance was detected in 4 patients of group 1 and 5 patients of group 2 while drug incompatibility in 3 patients of group 2. Demographic data of the patients are shown in table 1. Hundred and two patients in group 1 and 91 patients in group 2 completed treatment and there was no significant difference between the two groups ( $p=0.310$ ).

Eradication was achieved in 95 patients in group 1 and 78 patients in group 2. Eradication rates of *H.*

*pylori* in ITT and PP analysis were 89.6% and 93.1% in group 1, 78.8% and 85.7% in group 2, respectively. There was no significant difference between the two groups in terms of PP eradication rate ( $p=0.093$ ). Group 1 regimen reached a better eradication rate in ITT analysis than group 2 and this was statistically significant ( $p=0.033$ ) (Table 2).

### Discussion

*H. pylori* colonization was estimated to increase gastric cancer risk by approximately ten times and determined as a class I carcinogen by the World Health Organization (10). The most commonly used treatment regimen for *H. pylori* worldwide is the triple combination of PPI, amoxicillin, and clarithromycin. However, *H. pylori* eradication rates with this triple treatment regimens decreased significantly in recent years (11,12). *H. pylori* resistance rates against antibiotics are increasing in most parts of the world. The widespread use of clarithromycin against both *H. pylori* and other bacterial infections (especially upper and lower respiratory tract infections) raised concerns regarding clarithromycin resistance against *H. pylori*, which requires to reconsider the effectiveness of clarithromycin regimen for *H. pylori* eradication. In a study in Japan, the rate of resistance to clarithromycin increased from 8.7% to 34.5% from 1997 to 2008 (13). In various studies conducted in our country, amoxicillin resistance was reported as 0%, clarithromycin resistance as 18.2-41.9%, metronidazole resistance as 35.5-45.5%, tetracycline resistance as 0-9.1%, and levofloxacin resistance as 18.2-29.5% (14-17).

**Table 1. Demographic data of the patients**

Parameter	Bismuth based quadruple therapy group (Group 1)	Bismuth based sequential therapy group (Group 2)	P
Number of patients, n	106	99	-
Median age (years)	45.8±11.8	44±12.7	NS
<b>Gender</b>			
Male, n (%)	46 (43.4)	41 (41.4)	NS
Female, n (%)	60 (56.6)	58 (58.6)	
Number of patients who completed therapy, n (%)	102 (96.2)	91 (91.9)	NS
<b>Reason to discontinue therapy</b>			
GIS intolerance (n)	4	5	NS
Drug incompatibility (n)	0	3	

n: Number, NS: Non-significant, GIS: Gastrointestinal system

**Table 2. Comparison of eradication rates between study groups**

	Group 1	Group 2	p
<b>ITT analysis</b>			
n/N	95/106	78/99	0.033
%	89.6	78.8	
(95% CI)	(83.8-95.4)	(70.8-86.9)	
<b>PP analysis</b>			
n/N1	95/102	78/91	0.093
%	93.1	85.7	
(95% CI)	(88.2-98)	(78.5-92.9)	

ITT: Intention-to-treat, PP: Per-protocol, CI: Confidence interval, n: Number of patients who were eradicated, N: Total number of patients, N1: Number of patients who completed the study

In regions with a resistance rate of clarithromycin exceeding 15%, it is advised in the Maastricht V Consensus report that, triple treatment with PPI-clarithromycin should be discontinued unless clarithromycin resistance is verified by a preliminary susceptibility testing and bismuth quadruple or non-bismuth quadruple concomitant treatments should be given. In addition, bismuth quadruple therapy is recommended as the first-line treatment in areas with high dual resistance to clarithromycin and metronidazole (8).

Bismuth is known to have cytoprotective effects in addition to antimicrobial effects on *H. pylori* in the gastric mucosa. Up to now, resistance against bismuth has not been reported. Mechanisms of bismuth activity against *H. pylori* is not fully known. Bismuth shows its anti-helicobacter activity by forming complexes in the bacterial wall and periplasmic space, by inhibiting different enzymes of *H. pylori* such as urease, fumarase, phospholipase, by inhibiting adenosine triphosphate synthesis of bacteria, and by preventing adhesion of *H. pylori* onto the gastric mucosa (18). There is a synergy between bismuth salts and antibiotics. For example, when metronidazole and bismuth are used together, metronidazole-resistant *H. pylori* strains become susceptible (19). For this reason, we preferred to administer bismuth in both treatment groups. Different combinations of antibiotics are used in bismuth based quadruple treatments. In our study, we obtained ITT eradication rates of 89.6% and PP eradication rates of 93.1% with bismuth based quadruple treatment regimen, which is acceptable for *H. pylori* eradication. In different

studies from our country, eradication rates for bismuth based standard quadruple treatment regimens were reported as 81.1% and 74.6% in ITT analysis and 86% and 75.6% in PP analysis, respectively (20,21). Unlike these studies, we preferred to use amoxicillin instead of tetracycline. Another study used the same therapy regimen as ours and obtained similar eradication rate of 93.9% in PP analysis (22). The period of treatment in these studies was 14 days. We also preferred a 14 days of treatment on both arms of our study. The Maastricht V Consensus report also recommends extending the duration of bismuth-based quadruple treatment to 14 days, unless 10-day treatments are locally proven effective (8).

There are various reports about levofloxacin-containing regimens, and the most important concern about the future of these regimens is the potential antibiotic resistance. Eradication success with sequential treatment regimens containing levofloxacin was reported as 81.3% and 78.0% in Korea (23) and as 98.4% and 96.8% in Italy (24), in PP and ITT analysis, respectively. Levofloxacin resistance in Turkey was reported between 18.2% and 29.5% (14-17). Using sequential levofloxacin therapy, Aydın et al. (25) achieved 82.5% eradication with ITT analysis and 86.7% eradication with PP analysis while Polat et al. (9) achieved 90.2% and 86.6% eradication rates, respectively. In addition to these regimes, we used bismuth in group 2. Our eradication rates in group 2 were 78.8% with ITT analysis and 85.7% with PP analysis, which were similar to other studies. Four patients in group 1 and 5 patients in group 2 could not complete the treatment because of GIS intolerance

while 3 patients in group 2 due to drug incompatibility. However, the difference between the groups was not statistically significant. The main limitations of our study are the retrospective design and the absence of investigation on antibiotic resistance. Prospective studies involving also antibiotic susceptibility results may help to improve eradication success.

## Conclusion

As a result, we achieved better eradication rate with bismuth quadruple treatment compared with bismuth sequential treatment in our study. Due to the drug incompatibility observed during sequential treatment, we recommend bismuth based quadruple therapy regimen as the first line eradication treatment.

## Ethics

**Ethics Committee Approval:** The study was approved by Non-invasive Clinical Research Ethics Committee of Aydın Adnan Menderes University Medical Faculty (protocol no: 2016/1009).

**Informed Consent:** The written informed consent of the patients' was not received due to archival scan and retrospective study.

**Peer-review:** Externally and internally peer-reviewed.

## Authorship Contributions

Concept: A.C., Design: A.C., Data Collection or Processing: M.Ç., Analysis or Interpretation: M.Ç., Literature Search: A.K., Writing: A.C., A.K.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

- Morgan DR, Crowe SE. *Helicobacter pylori* infection. In: Sleisenger MH, Fordtran JS, (Eds). *Sleisenger and Fordtran's Gastrointestinal and Liver Disease*. 10th ed. Philadelphia: Saunders, 2010; 856-67.
- Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of *Helicobacter pylori* infection. *Am J Gastroenterol* 2017; 112: 212-39.
- Roubaud Baudron C, Franceschi F, Salles N, Gasbarrini A. Extragastic diseases and *Helicobacter pylori*. *Helicobacter* 2013; 18: 44-51.
- Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of *Helicobacter pylori* infection: systematic review and meta-analysis. *Gastroenterology* 2017; 153: 420-9.
- Sezikli M, Çetinkaya ZA, Güzelbulut F, Yeşil A, Coşgun S, Kurdaş OÖ. Supplementing vitamins C and E to standard triple therapy for the eradication of *Helicobacter pylori*. *J Clin Pharm Ther* 2012; 37: 282-5.
- Avşar E, Tiftikçi A, Poturoğlu S, Erzin Y, Kocakaya O, Dinçer D, et al. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate vs. lansoprazole-based triple therapy for the eradication of *Helicobacter pylori* in dyspeptic patients. *Turk J Gastroenterol* 2013; 24: 316-21.
- Lee JY, Park KS. Optimal First-Line Treatment for *Helicobacter pylori* Infection: Recent Strategies. *Gastroenterol Res Pract* 2016; 2016: 9086581.
- Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of *Helicobacter pylori* infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; 66: 6-30.
- Polat Z, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, Uygun A. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of *Helicobacter pylori*. *Eur J Intern Med* 2012; 23: 165-8.
- Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. *Clin Microbiol Rev* 2006; 19: 449-90.
- Kadayifci A, Buyukhatipoglu H, Cemil Savas M, Simsek I. Eradication of *Helicobacter pylori* with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. *Clin Ther* 2006; 28: 1960-6.
- Onder G, Aydın A, Akarca U, Tekin F, Ozutemiz O, Ilter T. High *Helicobacter pylori* resistance rate to clarithromycin in Turkey. *J Clin Gastroenterol* 2007; 41: 747-50.
- Sasaki M, Ogasawara N, Utsumi K, Kawamura N, Kamiya T, Kataoka H, et al. Changes in 12-year first-line eradication rate of *Helicobacter pylori* based on tripletherapy with proton pump inhibitor, amoxicillin and clarithromycin. *J ClinBiochem Nutr* 2010; 47: 53-8.
- Çagdas U, Otag F, Tezcan S, Sezgin O, Aslan G, Emekdas G. [Detection of *Helicobacter pylori* and antimicrobial resistance in gastric biopsy specimens]. *Mikrobiyol Bul* 2012; 46: 398-409.
- Kalem F, Ozdemir M, Basaranoglu M, Toy H, Baysal B. *Helicobacter pylori* isolates recovered from antral gastric biopsies of patients with dyspeptic symptoms: Antimicrobial resistance of metronidazole, clarithromycin and amoxicillin. *Anatol J Clin Invest* 2012; 6:37-40.
- Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, Bolek BK, et al. Antimicrobial resistance of *Helicobacter pylori* strains to five antibiotics, including levofloxacin, in Northwestern Turkey. *Rev Soc Bras Med Trop* 2015; 48: 278-84.
- Ozbey SB, Cuneyt O, Murat K. Antibiotic resistance rates of *Helicobacter pylori* isolates and the comparison of E-Test and fluorescent in situ hybridization methods for the detection of clarithromycin resistant strains. *Mikrobiyol Bul* 2009; 43: 227-34.
- Alkim H, Koksall AR, Boga S, Sen I, Alkim C. Role of Bismuth in the Eradication of *Helicobacter pylori*. *Am J Ther* 2017; 24: e751-7.

19. Dore MP, Graham DY, Mele R, Marras L, Nieddu S, Manca A, et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for *Helicobacter pylori* infection. *Am J Gastroenterol* 2002; 97: 857-60.
20. Gokcan H, Oztas E, Onal IK. Different bismuth-based therapies for eradicating *Helicobacter pylori*: Randomized clinical trial of efficacy and safety. *Clin Res Hepatol Gastroenterol* 2016; 40: 124-31.
21. Unler GK, Teke Ozgur G, Gokturk HS, Karakoca A, Erinanc OH. A Comparison of Five Different Treatment Regimens as the First-Line Treatment of *Helicobacter pylori* in Turkey. *Helicobacter* 2016; 21: 279-85.
22. Kekilli M, Onal IK, Ocal S, Dogan Z, Tanoglu A. Inefficacy of triple therapy and comparison of two different bismuth-containing quadrupleregimens as a firstline treatment option for *Helicobacter pylori*. *Saudi J Gastroenterol* 2016; 22: 366-9.
23. Lee H, Hong SN, Min BH, Lee JH, Rhee PL, Lee YC, et al. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of *Helicobacter pylori* infection in Korea. *Dig Liver Dis* 2015; 47: 114-8.
24. Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for *Helicobacter pylori* eradication: a randomised trial. *Gut* 2010; 59: 1465-70.
25. Aydin A, Oruc N, Turan I, Ozutemiz O, Tuncyurek M, Musoglu A. The modified sequential treatment regimen containing levofloxacin for *Helicobacter pylori* eradication in Turkey. *Helicobacter* 2009; 14: 520-4.